Home › Funds › SYQUANT CAPITAL SAS › OCS
SYQUANT CAPITAL SAS position in OCS
OCULIS HOLDING AG · Health Care
SYQUANT CAPITAL SAS reported holding 375,000 shares of OCS (OCULIS HOLDING AG) in its Q3 2026 13F filing — a position valued at US$2.8M, representing 0.62% of its reported portfolio and ranking #21 among its reported holdings. SYQUANT CAPITAL SAS has disclosed OCS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SYQUANT CAPITAL SAS's OCS position evolved
SYQUANT CAPITAL SAS first disclosed a stake in OCS in Q4 2025 at 192,722 shares (US$3.8M). The position peaked in Q1 2026 at 222,867 shares, worth US$5.9M. Across 4 filings, SYQUANT CAPITAL SAS increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 375,000 shares valued at US$2.8M. Notable position changes include a 68% increase in Q2 2026 (shares fell 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 192.72K | $3.85M | New |
| Q1 2026 | 222.87K | $5.93M | Add |
| Q2 2026 | 375.00K | $5.20M | Add |
| Q3 2026 | 375.00K | $2.82M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCS and 13F data
OCS (OCULIS HOLDING AG) is a Health Care company. 65 other funds we track also report a position in OCS — the largest reported positions include EQT Fund Management S.a r.l. (US$64.9M), Gildi - lifeyrissjodur (US$64.3M), Pivotal bioVenture Partners Investment Advisor LLC (US$20.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCS
- EQT Fund Management S.a r.l. 6.95M sh · $64.92M · Q3 2026
- Gildi - lifeyrissjodur 2.43M sh · $64.32M · Q1 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.51M sh · $20.89M · Q2 2026
- Saturn V Capital Management LP 684.88K sh · $9.50M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 641.02K sh · $8.89M · Q2 2026
- Nan Fung Group Holdings Ltd 300.56K sh · $4.17M · Q2 2026
- Marble Bar Asset Management LLP 14.81K sh · $205.36K · Q2 2026
- DUPONT CAPITAL MANAGEMENT CORP 4 sh · $37.00K · Q3 2026
More on SYQUANT CAPITAL SAS
FAQ
How long has SYQUANT CAPITAL SAS held OCS?
SYQUANT CAPITAL SAS has disclosed OCS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is SYQUANT CAPITAL SAS's current position in OCS?
As of Q3 2026, SYQUANT CAPITAL SAS holds 375.00K shares of OCS (OCULIS HOLDING AG), valued at $2.82M, representing 0.62% of its reported portfolio and ranking #21.
Has SYQUANT CAPITAL SAS been buying or selling OCS?
In the latest 13F filing (Q3 2026), SYQUANT CAPITAL SAS held unchanged its position in OCS. The position peaked in Q1 2026 at 222.87K shares.
Which other funds hold OCS?
Other major institutional holders of OCS include EQT Fund Management S.a r.l., Gildi - lifeyrissjodur, Pivotal bioVenture Partners Investment Advisor LLC, among 65 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.